GSK expects to launch five cancer drugs by 2010

GlaxoSmithKline expects to launch five new cancer drugs within the next three years, the firm announced. GSK faces competition from Merck to produce the first lung cancer vaccine, but expects to be marketing Cervarix for cervical cancer; Pazopanib for renal cancer; Promacta to reduce bleeding and help cancer patients build up their platelet count; Rezonic for chemotherapy nausea; and Ofatumumab, an antibody to treat leukemia by 2010.

View Full Article in:

Independent (London) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC